Tafamidis ATTR Cm denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tafamidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tafamidis-Attr-Cm for Medical Necessity — and How to Build a Strong Appeal

Medical-necessity denials for tafamidis in ATTR cardiomyopathy (ATTR-CM) are UHC's most common denial type for this drug. They occur when the clinical documentation submitted with the prior-authorization request does not, in UHC's clinical reviewer's judgment, satisfy every criterion in UHC's coverage policy. These denials are not a statement that the drug is ineffective — they are a documentation gap finding, and the appeal process is specifically designed to correct that gap.

The most frequent shortfalls: (1) insufficient documentation of the ATTR-CM diagnosis and its subtype, (2) missing or incomplete cardiac assessment records, (3) failure to address every line of UHC's clinical criteria in the prescriber's letter, or (4) the prescriber's letter was not specific enough to the individual patient.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You are entitled to a full and fair review. Request the complete denial rationale and the specific clinical criteria that were not met. UHC must provide these under ERISA.
• Peer-to-peer review: Before filing the formal appeal, ask UHC whether a peer-to-peer call between your prescriber and UHC's medical reviewer is available. This can resolve documentation gaps faster than a written appeal.
• External review: If the internal appeal is denied, an IRO will apply its own medical-necessity standard — not UHC's. Federal law provides approximately four months to request external review. Expedited review is available for urgent cases.

## Documentation to Gather

1. ATTR-CM diagnosis records — echocardiograms, cardiac MRI reports, nuclear scintigraphy (pyrophosphate or DPD scan), genetic testing (if hereditary), and the interpreting physician's report. 2. Clinical severity documentation — functional assessment, NYHA classification from the chart, any relevant biomarker trends (described qualitatively by the prescriber, not by specific numbers you assert). 3. Prior treatment history — all prior cardiac medications with start/stop dates and clinical response documented. 4. Prescriber medical-necessity letter — this letter must address UHC's criteria point by point. Obtain UHC's current clinical coverage policy for tafamidis before writing the letter and cite each criterion explicitly. 5. Applicable guideline support — the prescriber should reference the relevant ACC/AHA or applicable cardiology guideline organization's endorsement of tafamidis for ATTR-CM.

## Criteria-Mapping Structure

| UHC Medical-Necessity Criterion | Documented Chart Evidence | |---|---| | Confirmed ATTR-CM diagnosis | [Diagnostic method, date, result] | | Subtype confirmed | [Wild-type or hereditary, confirmed by] | | Cardiac assessment on file | [Echo/MRI/scan date and key findings per prescriber] | | Prescriber specialty | [Cardiologist name, NPI, attestation] | | FDA indication match | [Attached label, highlighted indication] |

The appeal letter should close by requesting that UHC identify any remaining unmet criteria specifically, so that a supplemental submission can address them without delay.